"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical data highlighting its potential to deliver durable, long-term functional ...

The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...

In a cohort study of nearly 16,000 US patients with breast cancer who were prescribed a cyclin-dependent kinase (CDK) 4/6 inhibitor, only 46% underwent liver function testing in the 2 weeks before ...

The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, facilitated by the EXPERTS-ALS platform, according to a press release from ...

Scientists have uncovered a crucial weakness in the malaria parasite that could open the door to new treatments. Researchers identified a protein called Aurora-related kinase 1 (ARK1) that acts like a ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or ...

Merck Animal Health announced today the FDA approved atinvicitinib tablets (NUMELVI; Merck Animal Health), making it the first and only second-generation Janus kinase (JAK) inhibitor indicated for ...

A secondary stress signaling pathway in the response to optic axon injury is an unexpectedly strong contributor to both neurodegeneration and axon regenerative potential.